Clinical Trial: Safety and Efficacy of Immune Therapy for Condyloma
Study Status: Not yet recruiting
Recruit Status: Not yet recruiting
Study Type: Interventional
Official Title: Safety and Efficacy of Immune Therapy for Condyloma
Brief Summary: Cytokine-induced killer (CIK) cells will be co-cultured with HPV induced dendritic cells (DCs); HPV specific DC-CIK will be induced to Condylomata Acuminata patients using interferon, whose recurrence rate and total cost will be compared to Condylomata Acuminata patients only use interferon.
Detailed Summary:
Sponsor: Shenzhen Second People's Hospital
Current Primary Outcome: Condylomata Acuminata recurrence rate [ Time Frame: 6 months ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
- skin tissue HPV gene [ Time Frame: 6 months ]use PCR to testify skin tissue HPV gene
- side effect [ Time Frame: 6 months ]evaluate and record side effect of each group
Original Secondary Outcome: Same as current
Information By: Shenzhen Second People's Hospital
Dates:
Date Received: May 16, 2017
Date Started: June 1, 2017
Date Completion: June 30, 2019
Last Updated: May 16, 2017
Last Verified: March 2017